Showing 19,541 - 19,560 results of 103,152 for search '(( e fold decrease ) OR ( 5 ((point decrease) OR (((a decrease) OR (mean decrease)))) ))', query time: 1.83s Refine Results
  1. 19541

    Data_Sheet_1_Mapping of a Regulatory Site of the Escherichia coli ADP-Glucose Pyrophosphorylase.PDF by Jaina A. Bhayani (7426799)

    Published 2019
    “…Other potent activator analogs include 1,6-hexanediol bisphosphate (HBP) and pyridoxal 5′-phosphate (PLP). Recently, a crystal structure with FBP bound was reported (PDB ID: 5L6S). …”
  2. 19542
  3. 19543
  4. 19544
  5. 19545

    Datasheet1_Acquired von Willebrand syndrome (AVWS) type 2, characterized by decreased high molecular weight multimers, is common in children with severe pulmonary hypertension (PH)... by Ivonne Wieland (14112981)

    Published 2022
    “…Notably, 3 of 5 patients (60%) with normal VWF:Ac/VWF:Ag ratio >0.7 had abnormal VWF multimers, indicating AVWS type 2. …”
  6. 19546
  7. 19547

    (a) As the condensate is being squeezed in the <em>xy</em> plane, the peak value of the mathcal {F}_z increases with respect to ω<sub>⊥</sub>/ω, where ω<sub>⊥</sub> is the trapping... by Shu-Wei Song (557396)

    Published 2013
    “…<p><strong>Figure 5.</strong> (a) As the condensate is being squeezed in the <em>xy</em> plane, the peak value of the \mathcal {F}_z increases with respect to ω<sub>⊥</sub>/ω, where ω<sub>⊥</sub> is the trapping frequency in the squeezing direction. …”
  8. 19548
  9. 19549

    Structure and Bonding Properties of the Complex (η<sup>5</sup>-Diphenylfulvene)Mn(CO)<sub>3</sub><sup>+</sup> by Martin A. O. Volland (3077121)

    Published 2000
    “…As a result of the bending of the exo methylene group the positive charge at the metal is increased and at C9 decreased.…”
  10. 19550

    Reduced Long-Term Relative Survival in Females and Younger Adults Undergoing Cardiac Surgery: A Prospective Cohort Study by Tone Bull Enger (668126)

    Published 2016
    “…The observed 30-day, 1-, 3- and 5-year mortality rates were 2.2%, 4.4%, 8.2% and 13.8%, respectively, and remained constant throughout the study period. …”
  11. 19551

    Metallization of a Hypervalent Radical Dimer: Molecular and Band Perspectives by John S. Tse (1321242)

    Published 2010
    “…Variable pressure and temperature conductivity measurements on the bisthiaselenazolyl radical dimer [<b>1a</b>]<sub>2</sub> have established the presence of a weakly metallic state over the pressure range 5−9 GPa. …”
  12. 19552

    Metallization of a Hypervalent Radical Dimer: Molecular and Band Perspectives by John S. Tse (1321242)

    Published 2010
    “…Variable pressure and temperature conductivity measurements on the bisthiaselenazolyl radical dimer [<b>1a</b>]<sub>2</sub> have established the presence of a weakly metallic state over the pressure range 5−9 GPa. …”
  13. 19553

    Metallization of a Hypervalent Radical Dimer: Molecular and Band Perspectives by John S. Tse (1321242)

    Published 2010
    “…Variable pressure and temperature conductivity measurements on the bisthiaselenazolyl radical dimer [<b>1a</b>]<sub>2</sub> have established the presence of a weakly metallic state over the pressure range 5−9 GPa. …”
  14. 19554

    Metallization of a Hypervalent Radical Dimer: Molecular and Band Perspectives by John S. Tse (1321242)

    Published 2010
    “…Variable pressure and temperature conductivity measurements on the bisthiaselenazolyl radical dimer [<b>1a</b>]<sub>2</sub> have established the presence of a weakly metallic state over the pressure range 5−9 GPa. …”
  15. 19555

    Metallization of a Hypervalent Radical Dimer: Molecular and Band Perspectives by John S. Tse (1321242)

    Published 2010
    “…Variable pressure and temperature conductivity measurements on the bisthiaselenazolyl radical dimer [<b>1a</b>]<sub>2</sub> have established the presence of a weakly metallic state over the pressure range 5−9 GPa. …”
  16. 19556
  17. 19557
  18. 19558

    Table_2_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

    Published 2022
    “…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”
  19. 19559

    Image_2_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.tif by Xiao-yang Gong (13103400)

    Published 2022
    “…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”
  20. 19560

    Table_4_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

    Published 2022
    “…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”